🔗 Share this article

Given that the United States continues making unprecedented revisions to its vaccination guidelines, one figure appears unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on coronavirus vaccinations throughout the pandemic and has focused upon potential deaths following COVID-19 immunization in her short tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders were set to unveil sweeping changes to the pediatric immunization program recently, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with many the world with insufficient data for benefit. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for ending some pediatric shot schedules in the US in order to be more in line with the Danish model, a country with nationalized medicine and a population approximately the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Background

Dr. Høeg has no obvious experience in pharmaceutical research, oversight or leadership, which has been typical for past heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a major agency. She is not an expert in drug approvals.”

Former heads of the center would “grasp regulatory frameworks and the research of drug development”, noted Dr. Janet Woodcock. “Clearly, she lacks the type of experience that previous people who headed CBER have had.”

CDER has an immense portfolio at the agency, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and each of these need to be managed,” Dr. Woodcock said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial management aspect to the position, which supervises in excess of 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” the former official concluded.

Agency Reaction and Controversial Policies

When asked about concerns about Dr. Høeg's credentials and whether this assignment represents more teamwork among agency officials on vaccines, a representative responded that the “concerns stem from flawed presumptions”.

“This background aligns with the responsibilities of her position,” the spokesperson explained, pointing to the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s new priority voucher program, a controversial expedited drug-approval program that reportedly troubled her predecessors. “How are these drugs being picked for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he said, “the FDA seems to be moving towards more relaxed regulations of most medications, except for shots.”

Public Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if problematic, past, critics said. She released a research paper using non-validated public submissions to determine the rate of myocarditis after Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current administration encompassed changing regulations for recently developed shots and ending “optional” vaccines, she stated post-election on a online show. At the FDA, Høeg has reportedly proposed preventing adolescent males from receiving COVID-19 vaccinations.

“She is an thorough dogmatist who begins with her beliefs and tailors the evidence to accommodate the data in a very deceptive, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow skeptics, {like|